If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
These electrostatic forces can be large enough for material transfer between two surfaces. Most of these protocols have only been published recently and their respective advantages and disadvantages have not yet been tested against each other. It is therefore not yet clear how reliable these methods are and what level of preservation of the samples is required for them to work. ZooMS protocols can be valuable when working with cultural heritage objects as they support derivation of biological (and therefore location) data with minimal harm to the object.
=== Differential diagnosis === Ullrich congenital muscular dystrophy (UCMD) involves mutations on the same genes as Bethlem myopathy, but has a more severe presentation, with the ability to walk (ambulation) typically being lost between the ages of 5–15 years. Autosomal recessive myosclerosis myopathy is allelic to the COL6A2 gene, it includes multiple contractures of the joints with slender muscles which are infiltrated by connective tissue and fibrosis, giving them a firm, "woody" feel upon palpitation. The symptoms of Bethlem myopathy may overlap with other conditions including Emery–Dreifuss muscular dystrophy, congenital muscular dystrophies, limb girdle muscular dystrophies, FHL1-related myopathies (X-linked myopathy with postural muscle atrophy, reducing body myopathy, and scapuloperoneal myopathy), and some forms of Ehlers–Danlos syndrome. Tubular aggregate myopathy (TAM1 & TAM2) includes, among other symptoms, contractures, muscle weakness, and fatty atrophy of muscle. Typical to Bethlem myopathy 1 and 2 are the presence of multiple contractures. A contracture can be caused by a variety of reasons, from disease to lifestyle (see Muscle contractures). If the patient lacks multiple contractures, as well as lacks other common symptoms of Bethlem myopathy, and in addition has muscular symptoms which are not known to be associated with Bethlem myopathy such as muscle hypertrophy, exercise-induced (dynamic) symptoms rather than fixed muscle weakness (static) symptoms, or cardiac involvement such as arrhythmia, then other myopathies should be considered.
The longest-lived isotope, 247Cm, has half-life 15.6 million years; so any primordial curium, that is, present on Earth when it formed, would have decayed to undetectable levels by now. However, recent nearby sites of R-process nucleosynthesis process can generate 247Cm and 247Cm has been detected in geologic samples from deep ocean floor drill cores . Its past presence as an extinct radionuclide is detectable as an excess of its primordial, long-lived daughter 235U. Traces of 242Cm may occur naturally in uranium minerals due to neutron capture and beta decay (238U → 239Pu → 240Pu → 241Am → 242Cm), though the quantities would be tiny and this has not been confirmed: even with "extremely generous" estimates for neutron absorption possibilities, the quantity of 242Cm present in 1 × 108 kg of 18% uranium pitchblende would not even be one atom. Traces of 247Cm are also probably brought to Earth in cosmic rays, but this also has not been confirmed. There is also the possibility of 244Cm being produced as the double beta decay daughter of natural 244Pu. Curium is made artificially in small amounts for research purposes. It also occurs as one of the waste products in spent nuclear fuel. Curium is present in nature in some areas used for nuclear weapons testing.
Sources: en.wikipedia.org
Quinteiro, Javier; Baibai, Tarik; Oukhattar, Laila; Soukri, Abdelaziz; Seixas, Pablo; Rey-Méndez, Manuel (2011). "Multiple paternity in the common octopus Octopus vulgaris (Cuvier, 1797), as revealed by microsatellite DNA analysis" (PDF). Molluscan Research. 31 (1): 15–20. Bibcode:2011MollR..311.1.2Q. CiteSeerX 10.1.1.363.8342. doi:10.11646/mr.31.1.2. {{cite journal}}: Cite uses deprecated parameter |citeseerx= (help) "CephBase: Common octopus". Archived from the original on 17 August 2005. Photos of Common octopus in the Sealife Collection
Stalin's plans for the city included a network of broad avenues and roadways, some of them more than ten lanes wide, which—while significantly simplifying movement through the city—were constructed at the expense of many historical buildings and districts. Among the many losses from Stalin's demolitions were the Sukharev Tower, an old city landmark, as well as mansions and commercial buildings. The city's new status as the capital of a strongly secular nation made religiously significant buildings particularly vulnerable to demolition. Many of the city's churches—in most cases some of Moscow's oldest and most prominent buildings—were destroyed. Notable examples of this destruction include Kazan Cathedral and the Cathedral of Christ the Saviour. During the 1990s, both cathedrals were rebuilt. Many smaller churches, however, were lost.
As the evidence for most types of alternative medicine such as acupuncture is far from strong, the use of alternative medicine in regular healthcare can present an ethical question. Using the principles of evidence-based medicine to research acupuncture is controversial, and has produced different results. Some research suggests acupuncture can alleviate pain but the majority of research suggests that acupuncture's effects are mainly due to placebo. Evidence suggests that any benefits of acupuncture are short-lasting. There is insufficient evidence to support use of acupuncture compared to mainstream medical treatments. Acupuncture is not better than mainstream treatment in the long term. The use of acupuncture has been criticized owing to there being little scientific evidence for explicit effects, or the mechanisms for its supposed effectiveness, for any condition that is discernible from placebo. Acupuncture has been called "theatrical placebo", and David Gorski argues that when acupuncture proponents advocate "harnessing of placebo effects" or work on developing "meaningful placebos", they essentially concede it is little more than that. Medical doctors practicing acupuncture cannot agree upon the positions of acupuncture points, to the extent it has become meaningless to call them "points".
Although the ancient Egyptians did not always distinguish frankincense from other resins such as myrrh, references to incense from the land of Punt have been dated to the third millennium BCE. Incense trees being transported for cultivation in Thebes are depicted in the so-called "Punt Colonnade" at the mortuary temple of Hatshepsut. The Ebers Papyrus, from around 1500 BCE, provides some of the earliest evidence for frankincense used with intent as a possible therapy. The incense offering occupied a prominent position in the sacrificial legislation of the ancient Hebrews. The Book of Exodus (30:34–38) prescribes frankincense, blended with equal amounts of three aromatic spices, to be ground and burnt in the sacred altar before the Ark of the Covenant in the wilderness Tabernacle, where it was meant to be a holy offering—not to be enjoyed for its fragrance. The Book of Jeremiah (6:20) relates that frankincense was imported from Sheba during the 6th century BC Babylonian captivity. Frankincense is mentioned in the New Testament as one of the three gifts (with gold and myrrh) that the magi "from the East" presented to the Christ Child (Matthew 2:11).
Sources: en.wikipedia.org
== Further reading == Behar, Howard with Janet Goldstein. (2007). It's Not About the Coffee: Leadership Principles from a Life at Starbucks, 208 pages. ISBN 1-59184-192-5. Clark, Taylor. (2007). Starbucked: A Double Tall Tale of Caffeine, Commerce and Culture. 336 pages. ISBN 0-316-01348-X. Michelli, Joseph A. (2006). The Starbucks experience: 5 principles for turning ordinary into extraordinary, 208 pages. ISBN 0-07-147784-5. Pendergrast, Mark (2001) [1999]. Uncommon Grounds: The History of Coffee and How It Transformed Our World. London: Texere. ISBN 1-58799-088-1. Schultz, Howard. and Dori Jones Yang. (1997). Pour Your Heart Into It: How Starbucks Built a Company One Cup at a Time, 350 pages. ISBN 0-7868-6315-3. Simon, Bryant. (2009). Everything but the Coffee: Learning about America from Starbucks. 320 pages. ISBN 0-520-26106-2. Media Archived at Ghostarchive and the Wayback Machine: "How Starbucks Became An $80B Business". CNBC. January 10, 2019. Archived at Ghostarchive and the Wayback Machine: "Why Starbucks Failed In Australia". CNBC. June 26, 2018. Archived at Ghostarchive and the Wayback Machine: "Why Starbucks Is Struggling In South Africa". CNBC. October 23, 2019.
=== Neurotransmission === Inhibitory neurons in the central nervous system play a homeostatic role in the balance of neuronal activity between excitation and inhibition. Inhibitory neurons using GABA, make compensating changes in the neuronal networks preventing runaway levels of excitation. An imbalance between excitation and inhibition is seen to be implicated in a number of neuropsychiatric disorders.
In 2006, Valerie O'Neil, a Starbucks spokeswoman, said that the logo is an image of a "twin-tailed mermaid, or siren as she's known in Greek mythology". The logo has been significantly streamlined over the years. In the first version, the Starbucks siren was topless and had a fully visible double fish tail. The image was said by Starbucks to be based on a 16th-century "Norse" woodcut, although other scholars note that it is apparently based on a 15th-century woodcut in Juan Eduardo Cirlot's Dictionary of Symbols. Some scholars have identified the image as Melusine. The connection to Melusine has been questioned; Melusine was not linked to heraldic images of two-tailed mermaids until the late 19th century, making it possibly a late misidentification. In the second logo, which was used from 1987 to 1992, the siren's breasts were covered by her flowing hair, but her navel was still visible. The fish tail was cropped slightly, and the primary color was changed from brown to green, a nod to the Alma Mater of the three founders, the University of San Francisco. In the third version, used between 1992 and 2011, her navel and breasts are not visible at all, and only vestiges remain of the fish tails. The original "woodcut" logo has been moved to the Starbucks's Headquarters in Seattle. At the beginning of September 2006, and then again in early 2008, Starbucks temporarily reintroduced its original brown logo on paper hot-drink cups. Starbucks has stated that this was done to show the company's heritage from the Pacific Northwest and to celebrate 35 years of business.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.